Last updated: May 1, 2026
Reslizumab: Clinical Trials Update and Market Forecast
Reslizumab is an IV anti–IL-5 monoclonal antibody used for severe eosinophilic asthma and is marketed outside the US by multiple brands. The development and commercial outlook is shaped by (1) ongoing safety effectiveness evidence in eosinophilic asthma phenotypes and (2) competitive pressure from subcutaneous IL-5/IL-5R agents (notably benralizumab) and broader biologic sequencing. This update synthesizes the clinical-trial posture and builds a market projection based on current asthma biologic penetration, label breadth, route-of-administration dynamics, and expected erosion risk from competitors.
What is reslizumab’s current clinical posture in severe eosinophilic asthma?
Reslizumab clinical activity remains anchored in severe eosinophilic asthma programs after approval. The most decision-relevant question for near-term development is whether reslizumab is expanding indication breadth, improving durability claims, or retaining differentiation versus benralizumab (IL-5Rα) and mepolizumab/other IL-5 pathway drugs (route and dosing).
Key clinical trial patterns that continue to matter
- Endpoint durability and steroid-sparing: Studies and extensions typically focus on exacerbation reduction and maintenance of improved lung function with continued treatment.
- Eosinophil-threshold enrichment: Reslizumab trials are generally structured around eosinophil-driven populations, which supports payer and guideline targeting.
- Route and adherence: Reslizumab is IV, which influences persistence and switching relative to more convenient subcutaneous comparators.
Competitive implications for trial design
- IL-5R blockade (benralizumab) can drive deeper eosinophil depletion, which can translate into stronger real-world persistence advantages in some health systems.
- Sequencing pressures: payers increasingly want evidence that supports stepwise switching among biologics after inadequate response.
(Clinical-trial status varies by geography and sponsor; however, the therapeutic strategy remains stable: eosinophilic asthma with exacerbation prevention and steroid reduction, supported by long-term safety follow-up.)
What does the competitive landscape imply for reslizumab’s market share?
Reslizumab competes in the severe asthma biologic segment where IL-5 pathway drugs are the core therapeutic class. Market share depends less on mechanism and more on: eligibility criteria, dosing convenience, injection frequency, payer contracting, and real-world persistence.
Competitive set (mechanism and practical differentiators)
| Agent |
Target |
Route |
Typical dosing cadence (class-level) |
Competitive angle vs reslizumab |
| Reslizumab |
IL-5 |
IV |
weight-based infusion |
efficacy in eosinophilic asthma, but IV limits convenience |
| Mepolizumab |
IL-5 |
SC |
maintenance dosing |
SC convenience supports persistence and uptake |
| Benralizumab |
IL-5Rα |
SC |
maintenance dosing with interval changes |
deep depletion and dosing schedule can win contracts |
| Dupilumab |
IL-4Rα |
SC |
maintenance dosing |
expands beyond eosinophils; dual cytokine pathway |
Route-of-administration advantage is the main structural disadvantage reslizumab carries. In biologic asthma, SC delivery generally improves uptake and clinic throughput economics, shifting formulary decisions even when efficacy curves are similar.
How large is the severe eosinophilic asthma biologics market and where does reslizumab fit?
Market sizing for reslizumab is best treated as a subset of the broader severe asthma biologics market, then further restricted to eosinophilic phenotypes and to jurisdictions that list reslizumab on formulary at scale.
Market segmentation logic used for projection
- Step 1: Severe asthma addressable base
Severe asthma incidence is the denominator for biologic eligibility.
- Step 2: Biologic-treated share
Not all eligible patients receive biologics due to cost, access restrictions, and referral patterns.
- Step 3: IL-5 pathway share
Within biologics, IL-5/IL-5R drugs represent a major share of usage for eosinophilic disease.
- Step 4: Reslizumab share within IL-5 pathway
Reslizumab’s IV route limits adoption relative to SC peers.
Reslizumab share drivers
- Medical guideline alignment: eosinophil thresholds and exacerbation history drive patient identification.
- Reimbursement policies: prior authorization criteria and response requirements determine uptake velocity.
- Treatment switching dynamics: patients who start on an IL-5 pathway biologic may switch to a competitor if exacerbations persist or convenience issues dominate.
What is the market forecast for reslizumab through the next 5 years?
This projection uses a structured approach:
- start from the addressable severe asthma biologics base,
- apply IL-5 pathway share,
- apply reslizumab’s expected share given IV access friction and competitive switching,
- apply erosion from SC competitors and partial offset from patients remaining stable on reslizumab.
Forecast framework (directional and decision-oriented)
- Base case: steady-to-moderate contraction in reslizumab units in mature markets as SC competitors expand share; modest growth in access-expanding geographies offset part of the decline.
- Downside case: rapid formulary exclusion or aggressive contracting by SC competitors accelerates share loss.
- Upside case: stable demand due to physician preference in specific patient subgroups and continued reimbursement stability slows erosion.
Annual unit and revenue projection (range)
Because no single authoritative global sales series is provided in this input, the forecast is expressed as a range anchored to class-level demand trends and route friction.
| Year |
Expected direction vs prior year |
Revenue (global, range) |
Units (global, range) |
Main swing factors |
| 2025 |
Mild decline to flat |
Mid to low single-digit change |
Mid to low single-digit change |
SC competitor share and payer contracting |
| 2026 |
Decline |
Low single-digit to mid single-digit erosion |
Low single-digit to mid single-digit erosion |
Switches after inadequate response and persistence effects |
| 2027 |
Stabilization to decline |
Low single-digit erosion |
Low single-digit erosion |
Market maturation and geographic access expansion |
| 2028 |
Decline |
Mid single-digit erosion |
Mid single-digit erosion |
Competitor consolidation and line optimization |
| 2029 |
Further decline or plateau |
Low to mid single-digit erosion |
Low to mid single-digit erosion |
Residual stable patients vs switchers |
Interpretation for business planning: reslizumab is forecast to behave like a mature, branded niche biologic rather than a high-growth franchise, with growth constrained by IV convenience and by ongoing payer preference for SC options. The strategic implication is that pipeline expansion is the main lever to change the trajectory; absent label expansion, the default is gradual erosion.
What clinical and commercial risks could shift the projection?
Clinical risks
- Comparative effectiveness pressure: if head-to-head or real-world data in targeted subgroups favors SC IL-5/IL-5R agents, switching accelerates.
- Safety/tolerability signals in long-term use: any recurring safety pattern can constrain continuation rates.
Commercial risks
- Formulary redesign: pharmacy benefit and specialty pharmacy contracting can replace IV biosimilars/alternatives.
- Center-of-excellence throughput economics: infusion chair capacity can reduce patient scheduling flexibility.
Mitigants that protect revenue
- Stable responders: patients controlled on reslizumab maintain therapy if benefit outweighs inconvenience.
- Subgroup response: if specific eosinophil profiles respond particularly well, payers may keep access.
Where are the highest-leverage next steps for R&D and investment decisions?
R&D signals to prioritize
- Eosinophil stratification refinement to sharpen responder identification and reduce payer denial risk.
- Long-term durability datasets with clear exacerbation reduction over extended maintenance.
- Real-world persistence studies comparing time-on-treatment versus SC IL-5 pathway agents.
Investment lens
- Treat reslizumab as a value-retention asset with upside tied to differentiation beyond convenience, such as:
- subgroup efficacy,
- adherence/persistence improvement tactics (where feasible),
- or new label expansions that move it toward more mainstream biologic eligibility.
What do current labels and usage foundations indicate about reslizumab demand?
Reslizumab is used for severe eosinophilic asthma. Demand is structurally tied to:
- eligible patient identification through eosinophil counts and exacerbation history,
- continuity of therapy,
- and the ability of clinicians and payers to justify IV administration.
These foundations support a “maintenance” market dynamic: demand stays adequate when reimbursement stability holds and patients remain controlled; demand erodes when SC alternatives become the default contract choice.
Key Takeaways
- Reslizumab’s clinical program is anchored in severe eosinophilic asthma efficacy and long-term safety, with ongoing relevance for durability and exacerbation prevention endpoints.
- Market share is constrained by IV administration, which typically reduces uptake and persistence relative to SC IL-5/IL-5R competitors.
- The forecast expects mild-to-moderate global revenue erosion over the next 5 years, with stabilization possible in geographies where reimbursement remains stable and switching barriers persist.
- The main levers to change the trajectory are label expansion, improved responder stratification, and evidence that supports stronger real-world persistence versus SC alternatives.
FAQs
-
What drives reslizumab patient selection in severe asthma?
Eosinophil status, exacerbation history, and steroid dependence are the core selection variables that govern eligibility.
-
Why does route of administration matter so much for biologic asthma sales?
IV delivery adds scheduling and facility throughput friction, which affects persistence, switching, and payer comfort relative to SC options.
-
What is the biggest competitive threat to reslizumab?
SC IL-5/IL-5R agents that secure formulary position through convenience and contract leverage.
-
How does switching typically occur among biologic asthma patients?
Patients with inadequate control or payer-driven changes commonly switch after reassessment of exacerbation rate and eosinophil response.
-
What evidence most improves a reslizumab market outlook?
Durable exacerbation reduction data in targeted eosinophil subgroups plus real-world persistence and continuation outcomes versus SC comparators.
References
[1] AstraZeneca. Fasenra (benralizumab) prescribing information.
[2] GlaxoSmithKline. Nucala (mepolizumab) prescribing information.
[3] Regeneron/Sanofi. Dupixent (dupilumab) prescribing information.
[4] Reslizumab: prescribing information and regulatory review documents (by country and sponsor).
